Marc Martinez-Llordella

Company: Quell Therapeutics

Job title: Founder & Vice President Biology

Seminars:

Use of Engineered Regulatory T-Cells to Induce Immunologic Tolerance: Path to the Clinic 3:45 pm

• Rational and preliminary data to support the use of antigen-specific Tregs as a therapeutic approach • Engineering technologies to improve Treg efficacy in the clinical applicationRead more

day: Day 2 - Track B - Evening

Use of Engineered Regulatory T-Cells to Induce Immunologic Tolerance: Path to the Clinic 11:30 am

Rational and preliminary data to support the use of antigen-specific Tregs as a therapeutic approach Engineering technologies to improve Treg efficacy in the clinical application      Read more

day: Focus Day - Track A - Afternoon